Explore

GSK Awaits FDA Decision on Innovative Chronic Hepatitis B Drug

GSK Awaits FDA Decision on Innovative Chronic Hepatitis B Drug

GSK Awaits FDA Decision on Innovative Chronic Hepatitis B Drug

GSK Awaits FDA Decision on Hepatitis B Drug Bepirovirsen with Potential for Major Health Impact

GSK Awaits FDA Decision on Hepatitis B Drug Bepirovirsen with Potential for Major Health Impact

GSK Awaits FDA Decision on Hepatitis B Drug Bepirovirsen with Potential for Major Health Impact

Boehringer and Zealand's Obesity Drug Shows Promising Phase 3 Results

Boehringer and Zealand's Obesity Drug Shows Promising Phase 3 Results

Boehringer and Zealand's Obesity Drug Shows Promising Phase 3 Results

Paradigm Health and FDA Collaborate to Enhance Clinical Trial Review Process

Paradigm Health and FDA Collaborate to Enhance Clinical Trial Review Process

Paradigm Health has announced a collaboration with the U.S. Food & Drug Administration (FDA) to develop a new model for accelerating clinical trial execution and regulatory review. This initiative utilizes Paradigm Health's technology-enabled Study Conduct platform, which automates data collection and analysis, allowing for real-time review by the FDA. The collaboration aims to reduce the burden of monitoring, data entry, and trial costs, thereby speeding up regulatory review and improving the efficiency of U.S. clinical trials. The model is currently being tested in a Phase 2 trial sponsored by AstraZeneca and a Phase 1b trial sponsored by Amgen. The platform captures data from electronic health records and other sources, evaluates it algorithmically, and transmits only critical signals to the FDA and trial sponsors.

AstraZeneca Faces Scrutiny Over Cancer Drug Applications Amid FDA Concerns

AstraZeneca Faces Scrutiny Over Cancer Drug Applications Amid FDA Concerns

AstraZeneca Faces Scrutiny Over Cancer Drug Applications Amid FDA Concerns

Novo Nordisk's Stock Rises Amid Weak Eli Lilly Drug Uptake and Positive Clinical Trials

Novo Nordisk's Stock Rises Amid Weak Eli Lilly Drug Uptake and Positive Clinical Trials

Novo Nordisk's Stock Rises Amid Weak Eli Lilly Drug Uptake and Positive Clinical Trials

FDA Approves New Quadruplet Regimen for Transplant-Ineligible Multiple Myeloma Patients

FDA Approves New Quadruplet Regimen for Transplant-Ineligible Multiple Myeloma Patients

The U.S. Food and Drug Administration (FDA) has approved a new treatment regimen for adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). The regimen, known as DVRd, combines DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) with bortezomib, lenalidomide, and dexamethasone. This approval is based on the Phase 3 CEPHEUS study, which demonstrated a significant improvement in minimal residual disease (MRD)-negativity rates compared to the previous standard regimen. The study showed that DVRd achieved a 52.3% MRD-negativity rate at a median follow-up of 22 months, compared to 34.8% with the previous regimen. This marks the third indication for DARZALEX FASPRO® in transplant-ineligible patients, reinforcing its role in the treatment landscape for multiple myeloma.

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention

Mundipharma Reports Positive Results from Phase III Trial of Rezafungin for Fungal Disease Prevention

Rejuvenate Bio Crowdfunds Gene Therapy Development for Aging and Chronic Diseases

Rejuvenate Bio Crowdfunds Gene Therapy Development for Aging and Chronic Diseases

Rejuvenate Bio Crowdfunds Gene Therapy Development for Aging and Chronic Diseases

FDA Approves AstraZeneca's Saphnelo Autoinjector for Lupus Self-Use in the US

FDA Approves AstraZeneca's Saphnelo Autoinjector for Lupus Self-Use in the US

AstraZeneca's Saphnelo (anifrolumab) has received approval from the US Food and Drug Administration (FDA) for self-administration as a once-weekly autoinjector, known as the Saphnelo Pen, for adult patients with systemic lupus erythematosus (SLE). This approval is based on the Phase III TULIP-SC trial results, which demonstrated a significant reduction in disease activity compared to placebo in patients with moderate to severe SLE. The safety profile of the autoinjector is consistent with the intravenous infusion of Saphnelo. The approval is seen as a significant advancement in making the medication more accessible and convenient for patients. SLE is a serious autoimmune condition affecting millions worldwide, and the new administration option offers more flexibility in treatment.

Eli Lilly Expands Oncology Portfolio with $2.3 Billion Acquisition of Ajax Therapeutics

Eli Lilly Expands Oncology Portfolio with $2.3 Billion Acquisition of Ajax Therapeutics

Eli Lilly Expands Oncology Portfolio with $2.3 Billion Acquisition of Ajax Therapeutics

FDA Approves AstraZeneca's Saphnelo Pen for Self-Administration in Lupus Patients

FDA Approves AstraZeneca's Saphnelo Pen for Self-Administration in Lupus Patients

The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's Saphnelo (anifrolumab) for self-administration as a once-weekly autoinjector, known as the Saphnelo Pen, for adult patients with systemic lupus erythematosus (SLE). This approval is based on the results from the Phase III TULIP-SC trial, which demonstrated a significant reduction in disease activity for patients with moderate to severe SLE. The trial results, published in Arthritis & Rheumatology, showed that the subcutaneous administration of Saphnelo was both statistically significant and clinically meaningful compared to a placebo. The safety profile of the autoinjector was consistent with the known clinical profile of Saphnelo when administered intravenously. This development is seen as a major advancement in the treatment of lupus, offering patients a more convenient and accessible option.